significant need,” she said, “and it would be wonderful to have an additional option that’s a targeted agent.”
The trial included 1,186 adults with migraines that struck two to eight times per month, and were moderate to severe in intensity. About half were randomly assigned to take one dose of rimegepant the next time they had a migraine; the other half were given an identical-looking placebo tablet.
Patients used electronic diaries to rate their symptoms before and after taking the tablet.
Overall, the real drug was more effective in erasing, or at least easing, pain within two hours. Of rimegepant users, 58% said their pain had dissipated, versus 43% of placebo users.
Patients also rated their “most bothersome” symptom — whether it was pain, nausea or sensitivity to light or
